SCHEMBL6594993

SCHEMBL6594993

CN1c2ccc([N+](=O)[O-])cc2CS1(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.48
SIRT2 Q8IXJ6 1/20 0.47
CASP1 P29466 1/20 0.45
CASP3 P42574 1/20 0.45
CASP4 P49662 1/20 0.45
CASP7 P55210 1/20 0.45
CASP9 P55211 1/20 0.45
CASP6 P55212 1/20 0.45
SIRT6 Q8N6T7 1/20 0.45
ALDH1A1 P00352 6/20 0.44
GAA P10253 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13234005 0.80 BMPR1B (0.45) LMNASIRT2CASP1CASP3CASP4
SCHEMBL6593532 0.78 SIRT2 (0.40) LMNASIRT2CASP1CASP3CASP4
SCHEMBL6597900 0.78 ALDH1A1 (0.40) LMNASIRT2CASP1CASP3CASP4
SCHEMBL31714633 0.77 SIRT6 (0.42) LMNASIRT2CASP1CASP3CASP4
SCHEMBL3885369 0.75 SIRT2 (0.55) LMNASIRT2CASP1CASP3CASP4
SCHEMBL20525233 0.75 POLB (0.44) LMNASMN1; SMN2POLB
SCHEMBL16736615 0.75 L3MBTL1 (0.50) LMNACASP1CASP3CASP4CASP7
SCHEMBL6593277 0.74 ALDH1A1 (0.44) LMNASIRT2ALDH1A1GAASMN1; SMN2
SCHEMBL17453068 0.73 BMPR1B (0.48) ALDH1A1
SCHEMBL29945643 0.73 DPP7 (0.50) LMNASIRT2SIRT6ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268475-B1 NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS UPJOHN CO (US) 2004-09-22 EP disclosed
EP-1268475-A1 NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-01-02 EP disclosed
US-6365612-B2 Benzosultam oxazolidinone antibacterial agents PHARMACIA & UPJOHN COMPANY 2002-04-02 US disclosed
US-20010047018-A1 Novel benzosultam oxazolidinone antibacterial agents PHARMACIA & UPJOHN COMPANY 2001-11-29 US disclosed
WO-2001074812-A1 NOVEL BENZOSULTAM OXAZOLIDINONE ANTIBACTERIAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2001-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047018-A1 Novel benzosultam oxazolidinone antibacterial agents OXA1L, TUFM, MRPL21 LMNA 4037/4885SIRT2 841/4885CASP1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.